S2-E46 – Highlights from Paris NASH
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeting, an event with exciting scientific messages and insights.
September 16, 2021
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeting, an event with exciting scientific messages and insights.
NEW CONTENT: Suneil Hosmane joins Roger Green to discuss why he found the FDA Webcast so encouraging for liquid biomarkers
Manal Abdelmalek joins the Surfers to share expectations in advance of Friday’s FDA Webcast on NASH Drug Development
Louise Campbell questions the implication of APASL and ALEH endorsing “MAFLD” as Fatty Liver Disease nomenclature and Stephen Harrison discusses behind-the-scenes activities to resolve this issue
The Surfers and guests Vlad Ratziu and Mazen Noureddin discuss key lessons learned in 2020 about Drugs and Diagnostics
Dr Ian Rowe and Prof. Dr. Jörn M. Schattenberg joins the Surfers to explore the relationship between NAFLD and CVD in light of recent work questioning the strength of links between the two
Reviews of Phase 2 drug trials and diagnostic strategies reveal that NASH is close to multiple breakthroughs
Manal Abdelmalek joins the Surfers to review some of Saturday’s most exciting presentations and posters from AASLD 2020, followed by a discussion of an exciting new hand-held diagnostic
